(Q43807555)

English

Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment

scientific article published in December 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1 reference

based on heuristic

inferred from title

6

object named as

Blomqvist C

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

author name string

Vehmanen L

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Saarto T

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Elomaa I

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Mäkelä P

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Välimäki M

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

publication date

1 December 2001

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

2373-2378

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Relative contributions of aging and estrogen deficiency to postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative Computed Tomography of Vertebral Spongiosa: A Sensitive Method for Detecting Early Bone Loss After Oophorectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of early age at menopause on vertebral bone mass

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled Clinical Study on the Use of Dichloromethylene Diphosphonate in Patients with Breast Carcinoma Metastasizing to the Skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Palliative pamidronate treatment in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rates of change in bone mineral density of the spine, heel, femoral neck and radius in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of menopause on longitudinal bone loss from the spine.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of menopause on femoral and vertebral bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900317-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(01)00317-3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43807555&oldid=2103513813"